- Home
- NRIM vs ENGN Comparison
NRIM vs ENGN Comparison
Compare NRIM & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NRIM | ENGN |
|---|---|---|
| Founded | 1990 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 551.4M | 605.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NRIM | ENGN |
|---|---|---|
| Price | $26.98 | $8.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $22.71 |
| AVG Volume (30 Days) | 176.9K | ★ 236.5K |
| Earning Date | 01-23-2026 | 12-22-2025 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | ★ 91.08 | N/A |
| EPS | ★ 2.80 | N/A |
| Revenue | ★ $201,544,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.55 | N/A |
| P/E Ratio | $9.64 | ★ N/A |
| Revenue Growth | ★ 42.34 | N/A |
| 52 Week Low | $16.18 | $2.65 |
| 52 Week High | $28.21 | $11.14 |
Technical Indicators
Market Signals| Indicator | NRIM | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 50.87 |
| Support Level | $26.68 | $8.17 |
| Resistance Level | $27.71 | $9.81 |
| Average True Range (ATR) | 0.62 | 0.68 |
| MACD | -0.09 | -0.08 |
| Stochastic Oscillator | 34.30 | 39.13 |
Price Performance
Historical ComparisonAbout NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The Company operates in three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. It generates maximum revenue from the Community Banking segment which offers loan and deposit products to business and consumer customers in its market areas and operates nearly 20 branches throughout Alaska.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.